Code of Conduct
Effective September 30, 2026
PlexusDx is designed to provide adults with a secure and respectful platform for accessing independent healthcare services. Patients and users are expected to follow these standards.
Accurate information
Provide truthful and complete identity, location, contact, and health information. Promptly update clinically relevant information when appropriate.
Your account
Protect your login credentials. Do not impersonate another person, use another person's account, or create an account to obtain PlexusDx treatment for someone else.
Follow the treatment plan
Follow the independent clinician's instructions and do not independently change a prescribed dose or treatment plan. Prescription medication is for the patient for whom it was prescribed and must not be sold or transferred.
Respectful communications
Communicate respectfully with PlexusDx support personnel, independent clinicians, pharmacy personnel, and service partners. Harassment, deliberate interference with services, or fraudulent conduct is not permitted.
Platform integrity
Do not falsify records, bypass security controls, interfere with platform operation, misuse automated systems, or use PlexusDx for unlawful activity.
Consequences
PlexusDx may restrict or terminate platform access for material misuse, fraud, abusive conduct, security threats, or other serious violations, subject to applicable law and the independent medical provider's clinical responsibilities.
Contact
Questions about this Code of Conduct may be sent to support@plexusdx.com.
PlexusDx, Inc.
6110 McFarland Station Drive, #604
Alpharetta, GA 30004
support@plexusdx.com
Important information
Compounded medications are not approved by the FDA or reviewed for quality, safety, or efficacy.
Novo Nordisk, Inc. is the only United States company with FDA-approved products containing semaglutide, identified under the trade names Rybelsus®, Ozempic®, and Wegovy®.
Lilly USA LLC is the only United States company with FDA-approved products containing tirzepatide, identified under the trade names Zepbound® and Mounjaro®.
The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.
